To study effect of Vranropana Taila Guggulyadi Dhupana and both on Episiotomy

Randomized,controlled clinical study of single and combined effect of Vranropana Taila application and Guggulyadi Dhupana on Episiotomy

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/04/018655

Enrollment

300

Registered

2019-04-18

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O94- Sequelae of complication of pregnancy, childbirth, and the puerperium

Interventions

Intervention1: Vranropana Taila and Guggulyadi Dhupana: Vranropana Taila will be applied on Episiotomy for 2 times a day for 8 days dose - 2ml Guggulyadi Dhupana will be given on Episiotomy for 2 time

Eligibility

Inclusion criteria

Inclusion criteria: full term patient delivered with Episiotomy

Exclusion criteria

Exclusion criteria: patient with bleeding disorders severe anaemia DM GDM local skin disease of perineum HIV vdrl hbsag positive

Design outcomes

Primary

Measure	Time frame
To study the efficacy of single and combined effect of Vranropana Taila application and Guggulyadi Dhupana on EpisiotomyTimepoint: 8 days	—

Secondary

Measure	Time frame
to study Episiotomy to observe any adverse effect of Vranropana Taila application Guggulyadi Dhupana and combined effect on EpisiotomyTimepoint: 8 days	—

Countries

India

Contacts

Public Contactgitanjali vaiti

maharashtra arogya mandals sumatibhai shah ayurved mahavidyalaya

drkalpanaayare@mail.com7083839240

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026